Twin Tree Management
CNCE

Twin Tree Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Twin Tree Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-641
Closed -$8K – 1639
2019
Q1 		$8K Buy
+641
New +$9.45K ﹤0.01% 1230

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Twin Tree Management's CNCE Position: Q2 2019 in Review

Twin Tree Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 641 shares — an estimated $8K sold.

Twin Tree Management first reported a position in CNCE in Q1 2019 and held it in 1 quarter. The position peaked at $8K in Q1 2019. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

  • Twin Tree Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Twin Tree Management sold 641 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $8K.
  • Twin Tree Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Twin Tree Management's Concert Pharmaceuticals, Inc. position peaked at $8K in Q1 2019.
  • 87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Twin Tree Management's 13F filing for Q2 2019, filed 12 Aug 2019.